Product Description
An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ulixertinib)
Mechanisms of Action: ERK Inhibitor, ERK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: xCures
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Myelofibrosis
Phase 1: Colorectal Cancer|Melanoma|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05985954 |
NCI-2023-06254 | P1 |
Recruiting |
Colorectal Cancer |
2028-03-28 |
50% |
2024-08-27 |
Primary Completion Date|Primary Endpoints |
NCT03454035 |
LCCC1736 | P1 |
Recruiting |
Melanoma|Pancreatic Cancer |
2026-07-15 |
2025-09-12 |
Primary Completion Date|Primary Endpoints|Treatments |
|
NCT06773195 |
NCT06773195 | P2 |
Recruiting |
Myelofibrosis |
2028-01-01 |
50% |
2025-01-15 |
Primary Endpoints |